Avibactam free acid
Based on 94 publication(s) in Google Scholar
Avibactam (NXL-104) free acid is a covalent and reversible non-β-lactam β-lactamase inhibitor which inhibits β-lactamase TEM-1 and CTX-M-15 with IC50s of 8 nM and 5 nM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.27%
- CAS No.: 1192500-31-4
- Formula: C7H11N3O6S
- Molecular Weight:265.24
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Antibacterial Compound Library
HY-L049
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
EMA-Approved Drug Library
HY-L116
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Avibactam free acid
More- Nature. 2024 Aug;632(8026):893-902. [Abstract]
- Biosens Bioelectron. 2021 Dec 1:193:113526. [Abstract]
- Cell Rep. 2024 Nov 9;43(11):114962. [Abstract]
- J Clin Microbiol. 2023 May 23;61(5):e0164722. [Abstract]
- J Clin Microbiol. 2020 Aug 24;58(9):e00932-20. [Abstract]
- PLoS Pathog. 2024 Dec 31;20(12):e1012783. [Abstract]
- Int J Mol Sci. 2021 Mar 17;22(6):3051. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- Int J Antimicrob Agents. 2024 Jun 24:107256. [Abstract]
- Int J Antimicrob Agents. 2024 May 14:107206. [Abstract]
- Antibiotics (Basel). 2024 May 1, 13(5), 416.
- RSC Adv. 2023 Nov 30;13(49):34884-34890. [Abstract]
- Antibiotics (Basel). 2023 Jul 20;12(7):1212. [Abstract]
- Antibiotics (Basel). 2022 Sep 20;11(10):1280. [Abstract]
- Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
- Antibiotics (Basel). 2021 Sep 14;10(9):1110. [Abstract]
- Int J Antimicrob Agents. 2018 Aug;52(2):269-271. [Abstract]
- Antimicrob Agents Chemother. 2026 Jun 3;70(6):e0126725. [Abstract]
- Antimicrob Agents Chemother. 2026 Mar 23:e0186025. [Abstract]
- Antimicrob Agents Chemother. 2026 Mar 4;70(3):e0126325. [Abstract]
- Antimicrob Agents Chemother. 2025 Apr 14:e0179724. [Abstract]
- Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0173624. [Abstract]
- Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0151824. [Abstract]
- Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0077524. [Abstract]
- Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0030123. [Abstract]
- Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0052823. [Abstract]
- Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. [Abstract]
- Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. [Abstract]
- Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. [Abstract]
- Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0240221. [Abstract]
- Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00409-20. [Abstract]
- Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02025-19. [Abstract]
- Antimicrob Agents Chemother. 2019 Sep 16;63(12):e01515-19. [Abstract]
- Antimicrob Agents Chemother. 2019 Aug 23;63(9):e01374-19. [Abstract]
- J Infect Dis. 2019 Jul 2;220(3):484-493. [Abstract]
- Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01809-18. [Abstract]
- Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00873-18. [Abstract]
- Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00433-18. [Abstract]
- Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18. [Abstract]
- Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00282-18. [Abstract]
- Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02260-16. [Abstract]
- Int J Infect Dis. 2025 Dec 4:163:108279. [Abstract]
- Int J Infect Dis. 2021 May:106:415-420. [Abstract]
- Int J Infect Dis. 2020 Apr;93:252-257. [Abstract]
- BMC Microbiol. 2020 Jun 29;20(1):187. [Abstract]
- BMC Microbiol. 2019 Nov 1;19(1):240. [Abstract]
- iScience. 2025 Mar 28;28(5):112311. [Abstract]
- Sci Rep. 2022 Oct 7;12(1):16814. [Abstract]
- Open Forum Infect Dis. 2026 Mar 26.
- Microbiol Spectr. 2025 Sep 2;13(9):e0019825. [Abstract]
- ACS Infect Dis. 2025 Apr 1. [Abstract]
- Open Forum Infect Dis. 2024 Oct 11;11(11):ofae611. [Abstract]
- Microbiol Spectr. 2024 Oct 3;12(10):e0095324. [Abstract]
- Microbiol Spectr. 2023 Dec 12;11(6):e0304723. [Abstract]
- Microbiol Spectr. 2023 Jun 15;11(3):e0069223. [Abstract]
- Microbiol Spectr. 2023 Feb 14;11(1):e0303822. [Abstract]
- Microbiol Spectr. 2022 Oct 26;10(5):e0203522. [Abstract]
- Microbiol Spectr. 2022 Oct 26;10(5):e0139022. [Abstract]
- ACS Infect Dis. 2021 Aug 13;7(8):2425-2436. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2026 Jan 19;81(2):dkaf495. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- J Antimicrob Chemother. 2025 Oct 27:dkaf388. [Abstract]
- J Antimicrob Chemother. 2025 Sep 29:dkaf360. [Abstract]
- J Antimicrob Chemother. 2024 Jun 3;79(6):1309-1312. [Abstract]
- J Antimicrob Chemother. 2023 Apr 3;78(4):983-990. [Abstract]
- J Antimicrob Chemother. 2022 Sep 30;77(10):2803-2808. [Abstract]
- J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. [Abstract]
- J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. [Abstract]
- J Antimicrob Chemother. 2020 Sep 1;75(9):2609-2615. [Abstract]
- J Antimicrob Chemother. 2017 Jul 1;72(7):1930-1936. [Abstract]
- J Antimicrob Chemother. 2017 Sep 1;72(9):2483-2488. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Sep 29. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):571-585. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):277-284. [Abstract]
- Infect Drug Resist. 2026 May 8;19.
- Infect Drug Resist. 2021 Jun 30;14:2499-2507. [Abstract]
- Infect Drug Resist. 2020 Aug 18;13:2883-2890. [Abstract]
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- Adv Ther (Weinh). 2024 Jan 12.
- Biomed Res Int. 2018 Jul 2:2018:3579832. [Abstract]
- Int J Med Microbiol. 2021 Oct;70(10). [Abstract]
- Int J Med Microbiol. 2020 Jul;69(7):928-931. [Abstract]
- Microb Drug Resist. 2020 Apr;26(4):334-340. [Abstract]
- Acta Microbiol Immunol Hung. 2021 Jul 29. [Abstract]
- J Infect Dev Ctries. 2021 Mar 31;15(3):404-414. [Abstract]
- Res Sq. 2026 Mar 9.
- Res Sq. 2026 Mar 10.
- bioRxiv. 2026 Jan 23.
- University of Skovde. 2025.
- Seoul National University. 2025 Feb.
- bioRxiv. 2024 Sep 25:2024.09.25.615047. [Abstract]
- Preprints. 2023 Jun 21.
- bioRxiv. 2021 Mar 13.
Customer Validation & Images
-
RT-PCR
-
WB
-
WB
-
In Vivo Efficacy Study
-
Bio/Physico-chemical Assay
All Beta-lactamase Isoforms
MoreAll Antibiotic Isoforms
More
Biological Activity
IC50: 5 nM (CTX-M-15), 8 nM (TEM-1)[1]
Avibactam is a molecule with little antibacterial activity, that inhibits class A and C β-lactamases, but not metallo types and Acinetobacter OXA carbapenemases[2].
Ceftazidime (HY-B0593)-Avibactam (0-256 mg/L) inhibits 16 blaKPC-2 positive and 1 of blaOXA-232 positive Klebsiella pneumonia growth with MIC50 and MIC90 for both 8 mg/L[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Avibactam (64 mg/kg; s.c.; once) shows mean estimated half-life in plasma in the terminal phase of 0.24 h in Pseudomonas aeruginosa infected neutropenic mice with lung infection[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six-week-old BALB/c mice (female), K. pneumoniae strain Y8 infection model[4]
-
Dosage:0.375 mg/g in combination with Ceftazidime
-
Administration:Subcutaneous injection, 4 h post infection and given every 8 h for 10 days
-
Result:70% of infection group mice died within 4 days, and all mice in the PBS group died within 13 days. All treatment group mice survived at 10 days post infection with the antibiotic applied every 8 h, whereas 100% of mice in this group died within 4 days after the antibiotic treatment stopped. The spleen and liver of treatment group mice showed lower CFU counts, as compare with that of infected group.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1192500-31-4
-
Appearance Solid
-
Molecular Weight 265.24
-
Formula C7H11N3O6S
-
Color White to off-white
-
SMILES
O=S(ON1[C@]2([H])CC[C@@H](C(N)=O)[N@@](C2)C1=O)(O)=O
-
Synonyms
NXL-104 free acid
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (94)
-
Journal Impact Factor
-
Most Recent
-
Nature
2024 Aug;632(8026):893-902. PMID: 39048820 -
Biosens Bioelectron
Rapid personalized AMR diagnostics using two-dimensional antibiotic resistance profiling strategy employing a thermometric NDM-1 biosensor. [Abstract]2021 Dec 1:193:113526. PMID: 34325239
Avibactam free acid purchased from MedChemExpress. Usage Cited in: Biosens Bioelectron. 2021 Dec 1:193:113526. [Abstract]
Avibactam sodium (AVI: 6.3-50 mg/L) in the presence or absence of 200 mg/L ceftriaxone and/or 0.8 U/L CTX-M-14.
Avibactam free acid purchased from MedChemExpress. Usage Cited in: Biosens Bioelectron. 2021 Dec 1:193:113526. [Abstract]
Analysis of mixed mock samples containing 0.8 U/L each of NDM-1/CTX-M-14 were incubated with penicillin, ceftriaxone, cefepime, cefoxitin or meropenem (200 mg/L) in the presence and absence of 25 mg/L Avibactam sodium (AVI) for 15 min, then the NDM-1/CTX-M-14 treated and untreated antibiotic samples were analyzed.
-
Cell Rep
ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. [Abstract]2024 Nov 9;43(11):114962. PMID: 39522165
Avibactam free acid purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Nov 9;43(11):114962. [Abstract]
SREBP2 target gene transcript levels after treatment with Avibactam (0.69 μM, 24 h) analyzed by qPCR. Actin Beta (ACTB) was used as a reference gene.
Avibactam free acid purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Nov 9;43(11):114962. [Abstract]
S-acylation levels of SCAP in Huh7 cells treated with Avibactam (0.69 μM, 24 h).
Avibactam free acid purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Nov 9;43(11):114962. [Abstract]
Protein levels of SCAP and its downstream target proteins in Huh7 cells following treatment with Avibactam (0.69 μM, 24 h).
-
J Clin Microbiol
Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test. [Abstract]2023 May 23;61(5):e0164722. PMID: 37070979 -
J Clin Microbiol
NitroSpeed-Carba NP Test for Rapid Detection and Differentiation between Different Classes of Carbapenemases in Enterobacterales. [Abstract]2020 Aug 24;58(9):e00932-20. PMID: 32580949 -
PLoS Pathog
Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae. [Abstract]2024 Dec 31;20(12):e1012783. PMID: 39739989 -
Int J Mol Sci
Molecular Basis of AmpC β-Lactamase Induction by Avibactam in Pseudomonas aeruginosa: PBP Occupancy, Live Cell Binding Dynamics and Impact on Resistant Clinical Isolates Harboring PDC-X Variants. [Abstract]2021 Mar 17;22(6):3051. PMID: 33802668 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
Int J Antimicrob Agents
Resistance to aztreonam-avibactam among clinical isolates of E. coli is primarily mediated by altered penicillin binding protein 3 and impermeability. [Abstract]2024 Jun 24:107256. PMID: 38925228 -
Int J Antimicrob Agents
MultiRapid ATB NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. [Abstract]2024 May 14:107206. PMID: 38754526 -
-
RSC Adv
Metallo-β-lactamases immobilized by magnetic zeolitic imidazolate frameworks-8 for degradation of β-lactam antibiotics in an aqueous environment. [Abstract]2023 Nov 30;13(49):34884-34890. PMID: 38035241 -
Antibiotics (Basel)
Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in Acinetobacter baumannii. [Abstract]2023 Jul 20;12(7):1212. PMID: 37508308 -
Antibiotics (Basel)
Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae. [Abstract]2022 Sep 20;11(10):1280. PMID: 36289937 -
Antibiotics (Basel)
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]2021 Nov 3;10(11):1341. PMID: 34827279 -
Antibiotics (Basel)
Rapid Detection of Multiple Classes of β-Lactam Antibiotics in Blood Using an NDM-1 Biosensing Assay. [Abstract]2021 Sep 14;10(9):1110. PMID: 34572692 -
Int J Antimicrob Agents
Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals. [Abstract]2018 Aug;52(2):269-271. PMID: 29559273 -
Antimicrob Agents Chemother
Improved hydrolysis of piperacillin by OXA-48-like R214G variants, a selective advantage under piperacillin-tazobactam exposure. [Abstract]2026 Jun 3;70(6):e0126725. PMID: 42053451 -
Antimicrob Agents Chemother
Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. [Abstract]2026 Mar 23:e0186025. PMID: 41870042 -
Antimicrob Agents Chemother
A genomics-informed mechanism-based pharmacokinetic/pharmacodynamic model of cefiderocol and ceftazidime/avibactam against carbapenem-resistant Achromobacter xylosoxidans. [Abstract]2026 Mar 4;70(3):e0126325. PMID: 41586494 -
Antimicrob Agents Chemother
PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate. [Abstract]2025 Apr 14:e0179724. PMID: 40227072 -
Antimicrob Agents Chemother
Evaluation of two gradient diffusion tests to determine susceptibility to aztreonam and ceftazidime-avibactam in combination. [Abstract]2025 Mar 5;69(3):e0173624. PMID: 39918316 -
Antimicrob Agents Chemother
Prediction of higher ceftazidime-avibactam concentrations in the human renal interstitium compared with unbound plasma using a minimal physiologically based pharmacokinetic model developed in rats and pigs through microdialysis. [Abstract]2025 Mar 5;69(3):e0151824. PMID: 39912660 -
Antimicrob Agents Chemother
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]2024 Nov 6;68(11):e0077524. PMID: 39365068 -
Antimicrob Agents Chemother
An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from in vitro time-kill experiments against multidrug-resistant Klebsiella pneumoniae isolates. [Abstract]2023 Oct 18;67(10):e0030123. PMID: 37681977 -
Antimicrob Agents Chemother
The in vitro effect of new combinations of carbapenem-β-lactamase inhibitors for Mycobacterium abscessus. [Abstract]2023 Oct 18;67(10):e0052823. PMID: 37671880 -
Antimicrob Agents Chemother
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]2023 Jul 18;67(7):e0033923. PMID: 37255469 -
Antimicrob Agents Chemother
Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology. [Abstract]2023 Jun 15;67(6):e0160322. PMID: 37199612 -
Antimicrob Agents Chemother
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. [Abstract]2023 Feb 16;67(2):e0145922. PMID: 36688684 -
Antimicrob Agents Chemother
A Two Amino Acid Duplication, L167E168, in the Ω-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A β-Lactamase. [Abstract]2022 Jun 21;66(6):e0240221. PMID: 35647648 -
Antimicrob Agents Chemother
Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae. [Abstract]2020 Sep 21;64(10):e00409-20. PMID: 32660988 -
Antimicrob Agents Chemother
β-Lactamase of Mycobacterium tuberculosis Shows Dynamics in the Active Site That Increase upon Inhibitor Binding. [Abstract]2020 Feb 21;64(3):e02025-19. PMID: 31871087 -
Antimicrob Agents Chemother
2019 Sep 16;63(12):e01515-19. PMID: 31527021 -
Antimicrob Agents Chemother
Synergistic Combinations and Repurposed Antibiotics Active against the Pandrug-Resistant Klebsiella pneumoniae Nevada Strain. [Abstract]2019 Aug 23;63(9):e01374-19. PMID: 31307981 -
J Infect Dis
Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance. [Abstract]2019 Jul 2;220(3):484-493. PMID: 30923801 -
Antimicrob Agents Chemother
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa. [Abstract]2018 Dec 21;63(1). pii: e01809-18. PMID: 30323045 -
Antimicrob Agents Chemother
Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae. [Abstract]2018 Sep 24;62(10). pii: e00873-18. PMID: 30061285 -
Antimicrob Agents Chemother
The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination. [Abstract]2018 Jul 27;62(8). pii: e00433-18. PMID: 29784837 -
Antimicrob Agents Chemother
Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae. [Abstract]2018 Jul 27;62(8). pii: e00414-18. PMID: 29760136 -
Antimicrob Agents Chemother
First Penicillin-Binding Protein Occupancy Patterns of β-Lactams and β-Lactamase Inhibitors in Klebsiella pneumoniae. [Abstract]2018 May 25;62(6). pii: e00282-18. PMID: 29712652 -
Antimicrob Agents Chemother
2017 Mar 24;61(4). pii: e02260-16. PMID: 28115348 -
Int J Infect Dis
Susceptibilities of cefiderocol, meropenem-xeruborbactam, cefepime-taniborbactam, aztreonam-avibactam, and sulbactam-durlobactam against imipenem-non-susceptible Gram-negative bacilli in Taiwan. [Abstract]2025 Dec 4:163:108279. PMID: 41349864 -
Int J Infect Dis
Evaluation of NitroSpeed-Carba NP test for rapid identification among different classes of carbapenemases in Enterobacterales and Pseudomonas aeruginosa. [Abstract]2021 May:106:415-420. PMID: 33864920 -
Int J Infect Dis
Characterizing the role of porin mutations in susceptibility of beta lactamase producing Klebsiella pneumoniae isolates to ceftaroline and ceftaroline-avibactam. [Abstract]2020 Apr;93:252-257. PMID: 32061861 -
BMC Microbiol
Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China. [Abstract]2020 Jun 29;20(1):187. PMID: 32600252 -
BMC Microbiol
Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam. [Abstract]2019 Nov 1;19(1):240. PMID: 31675928 -
iScience
The oxacillinase variant, OXA-1152, in Pandoraea sputorum contributes to discrepancies in carbapenem resistance. [Abstract]2025 Mar 28;28(5):112311. PMID: 40454099 -
Sci Rep
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. [Abstract]2022 Oct 7;12(1):16814. PMID: 36207358 -
-
Microbiol Spectr
Emergence of drug-resistant Klebsiella pneumoniae phylogroups (K. quasipneumoniae and K. variicola) causing human infections. [Abstract]2025 Sep 2;13(9):e0019825. PMID: 40778769 -
ACS Infect Dis
Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease. [Abstract]2025 Apr 1. PMID: 40168319 -
Open Forum Infect Dis
Successful Treatment of Recurrent Extensively Drug-Resistant Elizabethkingia anophelis Bacteremia Secondary to Ventricular Assist Device-Associated Infection. [Abstract]2024 Oct 11;11(11):ofae611. PMID: 39494452 -
Microbiol Spectr
Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against Enterobacterales isolates. [Abstract]2024 Oct 3;12(10):e0095324. PMID: 39225487 -
Microbiol Spectr
In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients. [Abstract]2023 Dec 12;11(6):e0304723. PMID: 37982634 -
Microbiol Spectr
Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae. [Abstract]2023 Jun 15;11(3):e0069223. PMID: 37093051 -
Microbiol Spectr
PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. [Abstract]2023 Feb 14;11(1):e0303822. PMID: 36475840 -
Microbiol Spectr
2022 Oct 26;10(5):e0203522. PMID: 36000902 -
Microbiol Spectr
Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies. [Abstract]2022 Oct 26;10(5):e0139022. PMID: 35972286 -
ACS Infect Dis
Atypically Modified Carbapenem Antibiotics Display Improved Antimycobacterial Activity in the Absence of β-Lactamase Inhibitors. [Abstract]2021 Aug 13;7(8):2425-2436. PMID: 34191496 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989 -
J Antimicrob Chemother
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies. [Abstract]2026 Jan 19;81(2):dkaf495. PMID: 41549665 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
J Antimicrob Chemother
Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model. [Abstract]2025 Oct 27:dkaf388. PMID: 41140026 -
J Antimicrob Chemother
Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes. [Abstract]2025 Sep 29:dkaf360. PMID: 41016856 -
J Antimicrob Chemother
Performance of disk diffusion method for aztreonam in combination with avibactam against Enterobacteriales. [Abstract]2024 Jun 3;79(6):1309-1312. PMID: 38564262 -
J Antimicrob Chemother
In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. [Abstract]2023 Apr 3;78(4):983-990. PMID: 36775993 -
J Antimicrob Chemother
In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa. [Abstract]2022 Sep 30;77(10):2803-2808. PMID: 35848936
Avibactam free acid purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2022 Sep 30;77(10):2803-2808. [Abstract]
In vivo change in log10 cfu/thigh of each isolate treated with saline control, Ceftazidime 2 g IV q8h 2 h infusion HSR, Ceftazidime/Avibactam 2.5 g q8h 2 h infusion HSR or meropenem 2 g q8h 3 h infusion HSR for three P. aeruginosa with inserted GES β-lactamases. (a) PSA 2136, with inserted GES-1 (ESBL). (b) PSA 2137, with inserted GES-5 (carbapenemase). (c) PSA 2138, with inserted GES-15. P values in the boxes represent the results from one-way ANOVA; P values are presented if between-group differences were present. The x-axis describes the treatment HSR [MIC (mg/L), % fT>MIC]. CAZ, Ceftazidime; CAZ-AVI, Ceftazidime/Avibactam; MEM, meropenem.
-
J Antimicrob Chemother
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]2021 Jul 15;76(8):2071-2078. PMID: 33956969 -
J Antimicrob Chemother
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]2021 Feb 11;76(3):653-658. PMID: 33258923 -
J Antimicrob Chemother
Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. [Abstract]2020 Sep 1;75(9):2609-2615. PMID: 32591806 -
J Antimicrob Chemother
High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. [Abstract]2017 Jul 1;72(7):1930-1936. PMID: 28333323
Avibactam free acid purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2017 Jul 1;72(7):1930-1936. [Abstract]
Total β-lactamase activity for bacterial lysates is measured using the chromogenic substrate nitrocefin, with or without Avibactam at 4 mg/L. (b) GR20263 hydrolysis activity of different bacterial lysates is determined with or without Avibactam at 4 mg/L.
-
J Antimicrob Chemother
Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. [Abstract]2017 Sep 1;72(9):2483-2488. PMID: 28637339 -
Eur J Clin Microbiol Infect Dis
Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]2025 Sep 29. PMID: 41023358 -
Eur J Clin Microbiol Infect Dis
In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. [Abstract]2025 Mar;44(3):571-585. PMID: 39704920 -
Eur J Clin Microbiol Infect Dis
In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. [Abstract]2025 Feb;44(2):277-284. PMID: 39589655 -
-
Infect Drug Resist
In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China. [Abstract]2021 Jun 30;14:2499-2507. PMID: 34234477 -
Infect Drug Resist
Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance of Mycobacterium abscessus to Imipenem. [Abstract]2020 Aug 18;13:2883-2890. PMID: 32903882 -
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594 -
-
Biomed Res Int
In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates. [Abstract]2018 Jul 2:2018:3579832. PMID: 30065936 -
Int J Med Microbiol
In vitro synergistic activity of aztreonam (AZT) plus novel and old β-lactamase inhibitor combinations against metallo-β-lactamase-producing AZT-resistant Enterobacterales. [Abstract]2021 Oct;70(10). PMID: 34605763 -
Int J Med Microbiol
In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. [Abstract]2020 Jul;69(7):928-931. PMID: 32584214 -
Microb Drug Resist
SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible Klebsiella pneumoniae. [Abstract]2020 Apr;26(4):334-340. PMID: 31651221 -
Acta Microbiol Immunol Hung
Ceftazidime - Avibactam susceptibility among carbapenem-resistant Enterobacterales in a pilot study in Turkey. [Abstract]2021 Jul 29. PMID: 34324428 -
J Infect Dev Ctries
An unequivocal superbug: PDR Klebsiella pneumoniae with an arsenal of resistance and virulence factor genes. [Abstract]2021 Mar 31;15(3):404-414. PMID: 33839716 -
-
-
-
-
-
bioRxiv
Rapid Emergence of Resistance to Broad-Spectrum Direct Antimicrobial Activity of Avibactam. [Abstract]2024 Sep 25:2024.09.25.615047. PMID: 39386481 -
-
Solvent & Solubility
DMSO : 125 mg/mL (471.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.84 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ehmann DE, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8. [Content Brief]
[2]. Livermore DM, et al. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother. 2012 Jun;67(6):1354-8. [Content Brief]
[3]. Berkhout J, et al. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304. [Content Brief]
[4]. Zhang W, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018 Nov 21;7:142. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7702 mL | 18.8509 mL | 37.7017 mL | 94.2543 mL |
| 5 mM | 0.7540 mL | 3.7702 mL | 7.5403 mL | 18.8509 mL | |
| 10 mM | 0.3770 mL | 1.8851 mL | 3.7702 mL | 9.4254 mL | |
| 15 mM | 0.2513 mL | 1.2567 mL | 2.5134 mL | 6.2836 mL | |
| 20 mM | 0.1885 mL | 0.9425 mL | 1.8851 mL | 4.7127 mL | |
| 25 mM | 0.1508 mL | 0.7540 mL | 1.5081 mL | 3.7702 mL | |
| 30 mM | 0.1257 mL | 0.6284 mL | 1.2567 mL | 3.1418 mL | |
| 40 mM | 0.0943 mL | 0.4713 mL | 0.9425 mL | 2.3564 mL | |
| 50 mM | 0.0754 mL | 0.3770 mL | 0.7540 mL | 1.8851 mL | |
| 60 mM | 0.0628 mL | 0.3142 mL | 0.6284 mL | 1.5709 mL | |
| 80 mM | 0.0471 mL | 0.2356 mL | 0.4713 mL | 1.1782 mL | |
| 100 mM | 0.0377 mL | 0.1885 mL | 0.3770 mL | 0.9425 mL |
Avibactam free acid Related Classifications
HY-14879 Related Classifications
Powered by Bioz